Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

Fig. 5

PET/CT scans showing the clinical response of patient 8: Initial pretreatment scan showing melanoma metastatic to (A) retro-auricular scalp soft tissues and (B) a small ipsilateral neck node. In (C and D) similar cuts show dramatic worsening of postauricular disease and bulky neck lymph nodes after 4 cycles of ipilimumab plus nivolumab therapy. Clinical response to combination CKI + TT is shown in scalp lesion E), as well as the neck adenopathy (F) at 40 months from start of CKI. Due to residual low-level fluorodeoxyglucose uptake at both neck and post-auricular sites, both were biopsied, and a pathologic complete response was documented. The patient remains stable at over 9 months after discontinuation of all treatment

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us